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Abstract:	
Mycobacterium	tuberculosis	can	remain	dormant	
in	 the	host,	an	ability	 that	explains	 the	 failure	of	
many	 current	 tuberculosis	 treatments.	 Recently,	
the	 natural	 products	 cyclomarin,	 ecumicin,	 and	
lassomycin	 have	 been	 shown	 to	 efficiently	 kill	
Mycobacterium	 tuberculosis	 persisters.	 Their	
target	is	the	N-terminal	domain	of	the	hexameric	
AAA+	 ATPase	 ClpC1,	 which	 recognizes,	 unfolds,	
and	 translocates	 protein	 substrates,	 such	 as	
proteins	 containing	 phosphorylated	 arginine	
residues,	 to	 the	 ClpP1P2	 protease	 for	
degradation.	Surprisingly,	these	antibiotics	do	not	
inhibit	ClpC1	ATPase	activity,	and	how	they	cause	
cell	 death	 is	 still	 unclear.	 Here,	 using	 NMR	 and	
small-angle	 X-ray	 scattering,	 we	 demonstrate	
that	 arginine-phosphate	 binding	 to	 the	 ClpC1	N-
terminal	 domain	 induces	 millisecond	 dynamics.	
We	 show	 that	 these	 dynamics	 are	 caused	 by	
conformational	 changes	 and	 do	 not	 result	 from	
unfolding	 or	 oligomerization	 of	 this	 domain.	
Cyclomarin	 binding	 to	 this	 domain	 specifically	
blocks	these	N-terminal	dynamics.	On	the	basis	of	
these	results,	we	propose	a	mechanism	of	action	
involving	cyclomarin-induced	restriction	of	ClpC1	
dynamics,	 which	 modulates	 the	 chaperone	
enzymatic	 activity	 leading	 eventually	 to	 cell	
death.	
	
Introduction:		
 http://www.jbc.org/cgi/doi/10.1074/jbc.RA118.002251The latest version is at 
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Tuberculosis	 (TB)	 is	 a	 major	 public	 health	
problem	with	ten	million	people	infected	and	two	
million	dying	each	year	(1).	The	main	challenge	in	
TB	 treatment	 is	 the	 long	 duration	 of	 therapy	
required	for	a	cure,	as	the	resistance	of	TB	results	
from	its	ability	to	stay	dormant	for	long	periods	in	
the	 host.	 Most	 antibiotics	 require	 bacterial	
replication	for	their	action	and	this	dormant	state	
renders	 Mycobacterium	 tuberculosis	 (Mtb)	
resistant	 to	 bactericidal	 antibiotics.	 Aggravating	
this	 problem,	 Mtb	 has	 become	 increasingly	
resistant	 to	 existing	 antibiotics,	 and	 multidrug-
resistant	TB	(MDR-TB)	is	now	widespread	(1).		
The	 proteolytic	 complex	 formed	 by	 the	 proteins	
MtbClpP1	 and	 MtbClpP2	 and	 their	 hexameric	
regulatory	 ATPases,	MtbClpX	 and	MtbClpC1	 are	
essential	 in	 mycobacteria	 and	 have	 emerged	 as	
attractive	 targets	 for	 anti-TB	 drug	 development.	
The	 Clp	 ATP-dependent	 protease	 complex	 is	
formed	 by	 two	 heptameric	 rings	 of	 protease	
subunits	 (MtbClpP1	 and	 MtbClpP2)	 enclosing	 a	
central	 degradation	 chamber,	 and	 a	 hexameric	
ATPase	 complex,	MtbClpC1	 or	MtbClpX	 (2).	 The	
ClpC1/ClpX	 ATPases	 recognize,	 unfold	 and	
translocate	 specific	 protein	 substrates	 into	 the	
MtbClpP1P2	 proteolytic	 chamber,	 where	
degradation	occurs.	MtbClpC1	is	a	member	of	the	
class	II	AAA+	family	of	proteins,	which	contains	a	
N-terminal	 domain	 (NTD)	 and	 two	 distinct	 ATP-
binding	modules,	D1	and	D2	 (Fig.	1a).	The	active	
form	of	ClpC	is	a	homohexamer,	and	in	MtbClpC1	
and	 Synechococcus	 elongates	 ClpC	 ATP	 alone	 is	
essential	 and	 sufficient	 for	 efficient	 protein	
degradation	 in	 association	 with	 ClpP	 (3).	
However,	 B.	 subtilis	 ClpC	 (BsClpC)	 requires	 the	
binding	 of	 both	 ATP	 and	 the	 adaptor	 protein	
MecA	 for	 formation	 of	 the	 active	 hexamer.	 No	
homologous	adaptor	protein	has	been	described	
in	Mtb	(4)	but	it	remains	to	be	tested	if	MtbClpC1	
can	associate	with	a	MecA-like	protein.		
Recently,	 Clausen	 and	 coworkers	 demonstrated	
that	 BsClpC	 specifically	 recognizes	 proteins	
phosphorylated	 on	 arginine	 residues	 by	 the	
arginine	kinase	McsB	(5).		These	phosphorylation	
sites	 are	 often	 found	 in	 secondary	 structure	
elements	 and	 thus	 are	 accessible	 only	when	 the	
protein	 is	unfolded	or	misfolded.	This	 innovative	
work	 revealed	 a	 new	 pathway	 for	 selective	
degradation	of	misfolded	proteins	in	bacteria,	but	
the	 structural	 consequences	 of	 arginine-
phosphate	 (ArgP)	 binding	 to	 ClpC	 are	 unclear.	
Indeed,	 although	 the	 crystal	 structure	 of	BsClpC	
NTD	 shows	 two	 ArgP	 molecules	 bound	 to	 the	
protein,	 no	 significant	 structural	 changes	 were	
observed,	which	is	quite	surprising	since	arginine-
phosphorylated	 substrates	 (e.g.	 casein)	 can	
stimulate	 BsClpC	 ATPase	 activity	 and	 can	
promote	complex	oligomerization	(5).	 
The	potential	importance	of	MtbClpC1	as	a	novel	
drug	 target	 against	 TB	 has	 been	 emphasized	 by	
the	 recent	 findings	 by	 two	 independent	 groups	
that	pyrazinamide	 (PZA)	 resistant	 strains	 contain	
mutations	(Fig.	1b)	in	ClpC1	(6,	7).	PZA	is	a	critical	
first-line	TB	drug	used	with	isoniazid,	ethambutol	
and	rifampicin	for	the	treatment	of	TB	and	is	also	
frequently	used	 to	 treat	MDR-TB	 (1).	 In	 addition	
to	 PZA,	 three	 natural	 product	 antibiotics	 that	
specifically	 target	MtbClpC1	 have	 been	 recently	
discovered:	 cyclomarin	 (8,	 9),	 ecumicin	 (10)	 and	
lassomycin	(11).	Cyclomarin,	identified	(and	since	
synthetized	 by	 independent	 groups)	 is	
bactericidal	 against	 TB	 and	 is	 able	 to	 kill	 non-
replicating	 bacteria	 (9).	 Despite	 the	 absence	 of	
resistance	 mutations,	 ClpC1	 NTD	 was	 identified	
as	 the	drug	 target	using	affinity	chromatography	
with	 cyclomarin	 conjugated	 to	 sepharose	 (9).	
While	 the	 crystal	 structure	 of	 the	 NTD	 was	
identical	 with	 or	 without	 cyclomarin	 bound,	
observations	 in	 Mycobacterium	 smegmatis	
suggested	 that	 cyclomarin	 can	 increase	
proteolysis	 by	 the	 ClpC1P1P2	 machine	 (8,	 9).		
How	cyclomarin	binding	 to	 the	NTD	may	 lead	 to	
increased	proteolysis	 is	still	not	known.	Ecumicin	
is	 another	 potent	 natural	 antibiotic	 that	
efficiently	 kills	 Mtb	 persisters,	 and	 resistance	
mutations	 in	 ClpC	 fall	 within	 its	 NTD	 (fig	 1b).	
When	 tested	 in	 vitro,	 ecumicin	 increases	 ClpC1	
ATPase	activity	several	fold,	while	simultaneously	
compromising	 degradation	 of	 ClpC1P1P2	
substrates	 (10,	 12).	 Lassomycin,	 an	
actinomycetes	 ribosomally	 encoded	 cyclic	
peptide,	 is	 yet	 another	natural	 antibiotic	 able	 to	
kill	 Mtb	 persisters	 with	 efficiency	 (11).	 Despite	
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differing	 structurally	 from	 ecumicin,	 lassomycin	
also	activates	ATP	hydrolysis	by	ClpC1	ATPase	and	
resistant	mutants	map	 to	 a	 basic	 domain	 in	 the	
protein’s	NTD	(11).		
Due	 to	 their	 high	 molecular	 weights	 and	
structural	complexity,	these	natural	products	are	
challenging	 for	 structure-activity	 relationship	
studies,	 but	 compounds	 with	 similar	 modes	 of	
actions	 may	 be	 very	 attractive	 as	 drug	
candidates.	Comprehension	of	the	mechanism	of	
action	of	 these	compounds	will	provide	valuable	
insights	 for	 development	 of	 more	 effective	 TB	
drugs.	 Unfortunately,	 the	 intrinsic	 flexibility	 and	
exchange	dynamics	between	different	oligomeric	
states	of	ClpC1	impeded	so	far	structural	studies.	
For	 example,	 crystallization	 of	 BsClpC	 was	 only	
possible	 upon	 the	 removal	 of	 flexible	 loop	
regions,	rendering	the	protein	nonfunctional,	and	
at	 the	 same	 time	 underlining	 the	 importance	 of	
dynamics	 for	 the	 function	 of	 these	 complexes	
(13).	 For	 this	 purpose,	 nuclear	 magnetic	
resonance	(NMR)	and	small	angle	X-ray	scattering	
(SAXS)	offer	 important	advantages	 to	 investigate	
protein	 conformation	 in	 solution	 and	 test	 the	
effects	of	ligands.		
Here	 we	 study	 the	 interaction	 of	 these	 potent	
new	 antibiotics	with	 ClpC1	 by	 using	 state	 of	 the	
art	 NMR	 and	 SAXS	 in	 order	 to	 elucidate	 their	
mode	of	 action.	A	 proper	 comprehension	of	 the	
ways	 these	 drugs	 influence	 ClpC1	 mechanism	
may	also	clarify	how	the	family	of	AAA+	ATPases	
functions	upon	substrate	binding.	
	
Results:	
Drug	Binding	to	ClpC1	NTD	
It	 is	 now	 widely	 accepted	 that	 conformational	
heterogeneity	 of	 proteins	 can	 be	 an	 important	
factor	 in	 ligand	 binding	 and	 drug	mechanism	 of	
action	(14).	Indeed,	in	the	case	of	cyclomarin,	no	
significant	 changes	 of	 the	 ClpC1	 NTD	 X-ray	
structure	 were	 observed	 upon	 ligand	 binding.	
Therefore,	 it	 was	 proposed	 that	 hidden	
unexplored	conformations	could	be	the	basis	 for	
the	 compound’s	 specific	 actions	 (8).	 Although	
linking	conformational	heterogeneity	or	dynamics	
to	 protein	 function	 is	 a	 difficult	 task,	 NMR	 is	 a	
powerful	method	to	elucidate	such	phenomena.	
Full	 length	MtbClpC1	 contains	 849	 residues	 that	
form	 a	 functional	 hexamer	 of	 561	 kDa	 in	 the	
presence	 of	 ATP.	 The	 large	 size	 of	 this	 complex	
together	 with	 its	 low	 solubility	 and	 expression	
prohibit	 NMR	 studies	 of	 the	 full-length	 protein,	
even	when	perdeuterated	and	specifically	methyl	
labelled	 samples	 are	 used.	 To	 circumvent	 this	
problem,	we	cloned	and	expressed	separately	the	
MtbClpC1	domains:	NTD	(1-145	aa),	D1	(165-493	
aa),	D2	(494-849	aa),	NTD-D1	(1-493	aa)	and	D1-
D2	(165-849	aa).	With	the	exception	of	the	NTD,	
NTD-D1	 and	D2	 constructs,	 all	 the	 other	 yielded	
insoluble	 proteins	 when	 expressed.	 Moreover,	
the	 D2	 domain	when	 purified	 did	 not	 show	 any	
detectable	 ATPase	 activity	 and	 did	 not	 form	
oligomers	in	the	presence	of	ATP,	while	the	NTD-
D1	 construct	 was	 soluble	 when	 expressed	 in	
ArticExpress	 cells	 at	 4	°C,	but	precipitated	when	
ATP	was	added.		
Mutations	 in	 the	 NTD	 of	 MtbClpC1	 have	 been	
shown	 to	 confer	 resistance	 to	 cyclomarin,	
ecumicin,	lassomycin	and	PZA,	indicating	a	pivotal	
role	of	this	domain	(Fig1b).	This	16	kDa	domain	is	
easily	 accessible	 for	 solution	 state	 NMR	 even	
without	 perdeuteration.	 Therefore,	 we	 focused	
our	 work	 on	 MtbClpC1	 NTD	 and	 tested	 the	
effects	of	the	different	antibiotics	on	its	structure	
in	 solution.	 MtbClpC1	 NTD	 behaved	 as	 a	
homogeneous	 monomeric	 protein	 upon	 size	
exclusion	 chromatography	 (FigS1a)	 and	 dynamic	
light	scattering	(DLS,	FigS1a),	and	resulted	in	high	
quality	 NMR	 spectra	 with	 excellent	 peak	
dispersion,	 indication	 of	 a	 well-folded,	 globular	
protein	 (Fig2a).	 Two	 sets	 of	 assignment	
experiments	 were	 done.	 While	 at	 pH	 7.5,	 we	
were	unable	to	assign	loop	regions	due	to	amide	
exchange,	at	pH	6.0	we	were	able	 to	assign	95%	
of	all	residues	allowing	the	mapping	of	almost	the	
entire	 protein	 structure.	 ClpC1	 NTD	 consists	 of	
eight	 helices	 that	 fold	 as	 two	 repeats	 of	 a	 four-
helix	 motif	 sharing	 58%	 identity	 (Fig2b).	 A	 14	
amino	acid	 loop	between	helix	4	and	5	connects	
 by guest on A
pril 16, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 4 
the	 two	motifs	 (8).	 Analysis	 of	 the	backbone	 1H,	
13C	 and	 15N	 chemical	 shifts	 with	 TALOS+	 (15)	
shows	 that	 the	 predicted	 secondary	 structure	
elements	in	the	NTD	in	solution	are	highly	similar	
to	the	elements	in	the	crystal	structure	(Fig2b).		
We	 proceeded	 testing	 the	 effect	 of	 cyclomarin	
binding	 on	 MtbClpC1	 NTD	 spectra.	 When	
cyclomarin	 was	 added	 to	 the	 MtbClpC1	 NTD,	
large	 changes	 in	 the	 spectrum	 were	 observed	
(Fig2a).	 Similar	 changes	were	 observed	with	 the	
analogue	desoxycyclomarin	 (Fig	S1b)(16).	 In	 fact,	
given	 the	 amplitude	 of	 chemical	 shift	
perturbations	 (CSP),	 a	 new	 set	 of	 assignment	
experiments	was	 required	 to	 identify	 the	 shifted	
residues.	The	 large	magnitude	of	 the	CSP	 (Fig2c)	
observed	 is	 likely	 a	 consequence	 of	 the	 rich	
content	 of	 aromatic	 residues	 in	 the	 cyclomarin	
molecule	 and	 the	 corresponding	 ring-current	
effect.	As	the	chemical	shift	 is	very	sensitive	to	a	
change	 in	 the	 local	 chemical	 environment,	 we	
were	 able	 to	map	 the	 compound	binding	 site	 to	
the	 region	 between	 helix	 1	 and	 5	 (Fig2d)	 in	
agreement	 with	 the	 X-ray	 structure	 of	 this	
domain	in	the	presence	of	bound	cyclomarin	(8).	
Analysis	 of	 the	 backbone	 amide,	 CO,	 Ca	 and	 Cb	
chemical	 shifts	with	TALOS+	 (15)	 shows	 that	 the	
predicted	 secondary	 structure	 elements	 in	 the	
cyclomarin	 bound	 NTD	 in	 solution	 are	 highly	
similar	 to	 the	 elements	 in	 the	 crystal	 structure	
(Fig	S1d)	excluding	major	changes	 in	 the	domain	
secondary	structure.	
Based	on	the	location	of	the	resistance	mutations	
(Fig1b),	 ecumicin	 was	 proposed	 to	 target	 the	
MtbClpC1	 NTD	 as	 well	 (10).	 For	 this	 reason,	 we	
tested	 if	 we	 could	 observe	 similar	 effects	 for	
ecumicin,	 as	 we	 did	 for	 cyclomarin	 by	 NMR.	
Compared	 to	 cyclomarin,	 ecumicin	 only	 caused	
modest	 spectral	 changes	 (Fig	 S2).	 These	 small	
perturbations	did	not	indicate	a	strong	binding	of	
ecumicin	 to	 the	 MtbClpC1	 NTD	 and	 were	
inconsistent	 with	 previous	 biochemical	 data	
where	 ecumicin	 was	 found	 to	 be	 a	 potent	
inhibitor	of	MtbClpC1	degradation	of	 casein,	but	
a	 stimulator	 of	MtbClpC1	 ATPase	 activity	 (result	
confirmed	 here,	 Fig	 S2d)	 (10).	 Consequently,	we	
tested	 ecumicin	 binding	 to	 the	 NTD	 using	
isothermal	 titration	 calorimetry	 (ITC).	 While	 we	
were	 able	 to	 confirm	 the	 nanomolar	 Kd	 for	
cyclomarin	(8)	(Fig	S3),	we	were	unable	to	obtain	
a	 saturation	 curve	 with	 ecumicin	 under	 the	
conditions	used	(up	to	100	µM	ecumicin,	Fig	S3).	
In	 contrast	 to	 cyclomarin	 and	 ecumicin,	 the	
addition	 of	 PZA	did	 not	 result	 in	 any	 changes	 of	
NTD	NMR	spectra,	furthermore	no	binding	of	PZA	
was	observed	by	ITC	(Fig	S3).		
NTD	dynamics		
Analysis	 of	 15N	 backbone	 relaxation	 rates	 can	
provide	 detailed	 information	 about	 protein	
dynamics	 on	 different	 time	 scales.	 In	 particular	
motions	 in	 the	 μs-ms	 timescale,	 associated	with	
conformational	 changes	 between	 different	
states,	often	occur	 in	 sites	 important	 for	protein	
function	 (17,	 18).	 Studying	 the	 dynamics	 of	
MtbClpC1	NTD	 is	particularly	 interesting,	 since	 it	
acts	 as	 a	 ligand	 recognition	 site	 that	 has	 to	
convey	information	about	the	bound	state	to	the	
D1	and	D2	rings	for	ATP	driven	translocation	and	
unfolding.	 Given	 the	 very	 modest	 structural	
differences	of	 the	NTD	 in	 its	apo	and	cyclomarin	
bond	states,	we	reasoned	that	dynamics	may	be	
important	in	the	allosteric	process.	
In	 order	 to	 investigate	 whether	 such	 μs-ms	
motions	 are	 indeed	 relevant	 for	 the	 NTD,	 we	
performed	 Carr-Purcell-Meiboom-Gill	 (CPMG)	
relaxation-dispersion	 (RD)	 NMR	 experiments.	
Briefly,	 RD	 profiles	 monitor	 the	 effective	 spin	
relaxation	 rate	constant	 (R2,eff)	as	a	 function	of	a	
variable	 repetition	 rate,	 νCPMG,	 of	 refocusing	
pulses	 applied	 during	 a	 relaxation	 delay.	 The	
presence	of	conformational	dynamics	is	manifest	
as	 a	dependence	of	R2,eff	 on	νCPMG,	 i.e.	 “non-flat”	
RD	profiles.	Such	dispersions	arise	when	the	local	
environment	 around	 the	 atom	 under	
consideration	is	fluctuating	on	a	μs-ms	time	scale,	
either	 because	 of	 motion	 of	 the	 considered	
atom(s)	 or	 neighboring	 atoms,	 e.g.	 through	
binding	 events.	When	we	applied	 this	 technique	
to	 apo	 NTD,	 we	 observed	 flat	 RD	 curves	 for	 all	
backbone	 amides.	 Thus,	 this	 domain	 alone	 does	
not	 exhibit	 significant	 μs-ms	 motions.	
 by guest on A
pril 16, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 5 
Furthermore,	cyclomarin	binding	does	not	induce	
ms	dynamics	in	the	NTD.		
Arginine-Phosphate	 and	 arginine	
phosphorylated	proteins	bind	to	MtbClpC1	NTD	
In	B.subtilis	 phosphorylation	 of	 arginines	 targets	
certain	 proteins	 for	 ClpCP-mediated	 degradation	
(5).	 Phosphorylated	 proteins,	 are	 first	 detected	
and	 bound	 by	 the	 NTD	 of	 ClpC	 and	 then	
transferred	 to	 the	 D1	 domain	 for	 subsequent	
unfolding	 and	 degradation	 (5).	 Analyzing	 the	
MtbClpC1	 NTD	 sequence,	 we	 found	 that	 the	
binding	 site	 of	 ArgP	 in	 B.	 subtilis	 is	 strictly	
conserved	 in	 Mtb	 (Fig3a).	 Furthermore,	
comparing	 the	 overall	 structures	 of	 the	 two	
NTDs,	it	is	clear	that	they	are	structurally	identical	
with	 an	 RMSD	 of	 1.7	 Å	 (Fig	 S3b).	 This	 striking	
similarity	 motivated	 us	 to	 test	 if	MtbClpC1	 NTD	
could	 also	 bind	 ArgP.	 Indeed,	 using	 ITC	 we	
confirmed	that	NTD	could	bind	ArgP	with	a	Kd	of	
5.2	 µM	 (Fig3b),	 a	 similar	 value	 as	 reported	 for	
BsClpC	NTD	(5).	 In	addition,	a	pull	down	showed	
that	 McsB	 phosphorylated	 lysozyme	 and	 casein	
bind	to	ClpC1	NTD	while	no	binding	was	observed	
with	 the	control	 substrate	 (Fig	3c).	 Furthermore,	
as	previously	 reported	 for	BsClpC,	a	 large	excess	
of	 free	 ArgP	 was	 required	 to	 inhibit	 this	
association	 likely	 reflecting	a	 stronger	binding	of	
NTD	 to	 the	 protein	 substrate	 (Fig	 3c).	 Despite	
some	 residual	 binding	 of	 non-phosphorylated	
lysozyme,	a	similar	result	was	observed	when	full	
length	 ClpC1	 was	 used	 instead	 of	 isolated	 NTD	
(Fig	S3c).		
Addition	 of	 ArgP	 to	 MtbClpC1	 NTD	 resulted	 in	
strong	perturbations	of	its	backbone	amide	NMR	
spectrum	(Fig	3d).	This	effect	was	specific	to	ArgP	
since	no	 significant	 changes	were	observed	with	
unmodified	arginine	or	phosphoserine	(Fig	S4).		In	
contrast	 to	 the	 rather	 small	 changes	 in	 peak	
intensity	 observed	 upon	 cyclomarin	 or	 ecumicin	
addition,	 ArgP	 caused	 large	 changes	 in	 peak	
intensity,	with	45%	of	the	peaks	falling	below	the	
level	of	detection	 into	the	background	noise	 (Fig	
3e).	 	 As	 shown	 below,	 this	 decrease	 in	 intensity	
can	 indicate	 exchange	 events	 at	 the	 affected	
residues.	Interestingly,	these	residues	do	not	map	
exclusively	 to	 the	 putative	 binding	 site	 of	 ArgP,	
but	are	 localised	over	a	 large	part	of	 the	core	of	
the	 structure,	whereby	 helices	 2,	 3,	 6	 and	 7	 are	
most	 affected	 (Fig3e,	 3f).	 Using	 CPMG	 RD	
experiments,	 we	 could	 prove	 that	 the	 observed	
decrease	 in	 intensity	 is	 indeed	 caused	 by	
millisecond	 dynamics	 (Fig	 4a,	 4b).	 Surprisingly,	
these	 dynamics	 can	 be	 seen	 throughout	 the	
domain.	 In	 Fig.	 4a	 the	 affected	 residues	 and	 the	
ΔR2eff	 are	 plotted	 on	 the	 structure	 of	MtbClpC1	
NTD.	 Furthermore,	 we	 assume	 that	 the	 part	 of	
the	protein	showing	the	highest	degree	of	motion	
are	 the	 three	 helices	 with	 disappearing	
resonances	(refer	to	Fig3f).	
Although	CPMG	RD	experiments	provide	 residue	
resolved	direct	evidence	of	the	motions,	they	do	
not	 actually	 reveal	 what	 the	 underlying	 motion	
corresponds	 to.	 In	 the	 case	 of	 low	 affinity	
binding,	 ms	 dynamics	 can	 be	 also	 caused	 by	
on/off	 binding	 dynamics	 of	 the	 compound.	
Considering	 the	 ArgP	 Kd,	 we	 can	 calculate	 the	
population	 of	 free	 NTD	 with	 the	 concentrations	
of	ArgP	used	(2	mM),	which	results	in	full	domain	
saturation	 (calculated	 free	NTD	0.3	%).	 Fitting	of	
the	 CPMG	 RD	 data	 with	 the	 software	 Chemex	
provides	 an	 exchange	 rate	 between	 the	 ground	
and	 excited	 state,	 the	 population	 of	 the	 excited	
state	 and	 the	 chemical	 shift	 difference	 between	
the	 two	 states.	 The	 fitted	 population	 of	 the	
excited	 state	 (5	 %,	 Fig	 S5d)	 is	 not	 in	 agreement	
with	the	calculated	free	state	of	the	NTD	(0.3	%).	
Moreover,	 theoretical	 chemical	 shift	 differences	
of	 the	 excited	 state	 derived	 from	 fitting	 of	 the	
CPMG	 RD	 data	 with	 Chemex	 do	 not	 correlate	
with	 experimental	 chemical	 shift	 differences	
between	apo	and	ArgP	bound	NTD	(Fig	S5a).	 	To	
conclude,	 we	 confirmed	 that	 the	 excited	 state	
does	not	correspond	to	the	free	state	of	the	NTD,	
but	most	likely	to	a	different	conformation.	
Arginine	has	been	previously	 reported	 to	 reduce	
the	 melting	 point	 of	 some	 protein	 but	
paradoxically	 has	 been	 also	 suggested	 as	 a	
stabilizer	 for	 protein	 preparations	 (19-22).	 In	
order	to	discard	the	possibility	that	the	dynamics	
observed	 result	 from	 ArgP	 promoted	 unfolding	
we	 recorded	 far-UV	 circular	 dichroism	 (CD)	
spectra	of	MtbClpC1	NTD	with	and	without	ArgP	
present.	 In	 both	 cases,	 the	 spectra	 were	 typical	
for	 α-helical	 proteins	 with	 characteristic	minima	
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 6 
at	 ≈210	 nm	 and	 ≈222	 nm	 (Fig.	 5a).	 Additionally,	
we	 used	 chemical	 shift	 differences	 from	 the	
Chemex	 fitting	 of	 the	 CPMG	 RD	 data	 and	
compared	 these	 values	 with	 the	 chemical	 shift	
differences	 of	 the	 folded	 NTD	 and	 calculated	
random	 coil	 shifts	 derived	 from	 ncIDP	 (23)	
(FigS5b).	 Clearly,	 the	 fitted	 chemical	 shift	
differences	 do	 not	 correlate	 with	 the	 calculated	
random	 coil	 values.	 Thus,	 ArgP	 does	 not	 appear	
to	unfold	the	NTD	and	also	does	not	perturb	the	
secondary	structure	of	the	domain.		Alternatively,	
ArgP	might	induce	domain	oligomerization,	which	
would	 explain	 peaks	 disappearing	 by	 transient	
interactions	 between	 two	 ClpC1	 subunits.	
Analysis	 of	 the	 protein	 by	 DLS	 (FigS1)	 and	
Diffusion	 Ordered	 Spectroscopy	 (DOSY,	 FigS5e),	
however,	 excluded	 this	 hypothesis.	 Both	 ArgP	
and	 cyclomarin	 did	 not	 induce	 any	 change	 in	
MtbClpC1	NTD	oligomerization.		
Intrinsic	 aromatic	 fluorescence	 can	 be	 used	 to	
probe	 conformational	 changes	 upon	 ligand	
binding.	 While	MtbClpC1	 NTD	 does	 not	 contain	
any	 tryptophan	 residues,	 it	 contains	 3	 tyrosine	
residues	(Y27,	Y102	and	Y145),	which	can	be	used	
as	 probes	 for	 domain	 conformational	 changes	
(Fig	 S5f).	When	we	 tested	 the	 effect	 of	 ArgP	 on	
NTD	 fluorescence,	 we	 observed	 an	 increase	 in	
tyrosine	 fluorescence	 (Fig	 S5g)	 associated	with	a	
stabilization	 of	 the	 protein.	 NTD	 displayed	
cooperative	unfolding	with	an	apparent	Tm	of	69	
°C,	 this	 value	 was	 increased	 to	 79	 °C	 in	 the	
presence	of	ArgP	1	mM	(Fig	5b).		
An	alternative	approach	to	probe	conformational	
changes	 is	 the	 use	 of	 fluorescent	 probes.	 1-
Anilinonaphthalene-8-Sulfonic	 Acid	 (ANS)	 binds	
to	 hydrophobic	 regions	 in	 the	 protein,	 and	 ANS	
fluorescence	 increases	 substantially	 when	
proteins	 undergo	 changes	 that	 expose	
hydrophobic	 surfaces	 as	 normally	 occurs	 during	
protein	unfolding.	ANS	can,	however,	be	used	to	
detect	 subtle	 conformational	 changes,	 and	 we	
tested	 if	 ArgP	 binding	 leads	 to	 changes	 in	 ANS	
fluorescence.	 While	 ANS	 binding	 to	 MtbClpC1	
NTD	 resulted	 in	 an	 increase	 in	 fluorescence,	
indicating	 the	 presence	 of	 exposed	 hydrophobic	
surface,	 ArgP	 binding	 did	 not	 significantly	 alter	
fluorescence	 (Fig5c).	 Because	 cyclomarin	 has	
intense	 intrinsic	 fluorescence,	 it	 cannot	 be	 used	
in	the	previous	fluorescence	studies.	
	
Cyclomarin	restricts	ArgP-induced	dynamics	
			
The	 fact	 that	 cyclomarin	binding	does	not	 affect	
MtbClpC1	NTD	dynamics	 is	 inconsistent	with	 the	
prior	 proposal	 that	 cyclomarin	 acts	 by	 causing	
conformational	 changes	 in	 this	 domain	 (8).	 By	
contrast,	 ArgP	 leads	 to	 a	 significant	 increase	 in	
domain	 dynamics.	 We	 therefore	 tested	 if	
cyclomarin	 binding	 could	 either	 block	 ArgP-
recognition	 or	 ArgP-induced	 dynamics.	 Adding	
ArgP	 to	MtbClpC1	NTD	 prebound	 to	 cyclomarin,	
we	 observed	 significant	 changes	 in	 the	 1H-15N	
correlated	HSQC	 spectrum	 in	 the	 binding	 site	 of	
ArgP	 (Fig	 S6).	 This	 is	 consistent	 with	 our	 pull-
down	 results	 where	 no	 effect	 of	 cyclomarin	 on	
arginine	 phosphorylated	 proteins	 binding	 to	 the	
NTD	was	observed	(Fig3c).	However,	the	behavior	
of	 ArgP	 bound	 and	 ArgP/cyclomarin	 bound	 NTD	
was	 clearly	 different.	 Several	 peaks	 that	
disappeared	 upon	 ArgP	 binding,	 reappeared	
when	cyclomarin	was	added.	Instead	of	45%,	only	
25%	 of	 all	 peaks	 disappeared	 when	 cyclomarin	
was	 added	 together	 with	 ArgP.	 Related	 to	 the	
spectral	 changes,	 the	 most	 striking	 difference	
between	 ArgP	 and	 ArgP/cyclomarin	 binding	 are	
the	dynamic	properties	of	the	NTD.	When	ArgP	is	
bound	to	the	NTD	most	observed	residues	exhibit	
µs-ms	dynamics.	These	dynamics	can	however	be	
completely	 abolished	 by	 addition	 of	 cyclomarin.	
In	 ArgP/cyclomarin	 bound	 NTD,	 not	 a	 single	
residue	showed	µs-ms	dynamics	exactly	as	occurs	
in	apo	MtbClpC1	NTD	(Fig	4).	Cyclomarin	binds	to	
a	 hydrophobic	 “bed”	 formed	 by	 two	
phenylalanines	 in	 the	 symmetric	 axis	 of	 the	
domain	 (8),	 which	 by	 stabilizing	 the	 core	 of	 the	
domain,	 	 presumably	 explains	 how	 it	 can	 block	
completely	NTD	domain	dynamics.	
	
Cyclomarin	 prevents	 ArgP	 inhibition	 of	 FITC-
casein	degradation	
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 7 
The	 primary	 function	 of	 ClpC1	 is	 to	 recognize	
certain	 cellular	 proteins	 and	 to	 unfold	 and	
translocate	 them	 into	 ClpP1P2	 for	 degradation,	
although	 it	 is	 also	 able,	 at	 least	 in	 vitro,	 to	
catalyze	 the	 refolding	 of	 some	 proteins	 (2,	 24).	
Until	 the	 discovery	 of	 ArgP	 in	 BsClpC	 no	
recognition	 signal	 for	 ClpC	 was	 known.	 In	 the	
presence	 of	 the	 cofactor	 MecA,	 BsClpC	 can	
catalyze	 the	 degradation	 of	 unfolded	 proteins,	
such	 as	 casein.	 However,	 ArgP	 (1mM)	 is	 able	 to	
block	 MecA-dependent	 proteolysis,	 apparently	
because	 the	 binding	 site	 of	 ArgP	 overlaps	 with	
the	 contact	 site	 of	 MecA	 and	 BsClpC’s	 NTD	 (5).	
This	 observation	 clearly	 suggests	 that	 ClpC	 has	
two	 alternative	 mechanisms	 for	 substrate	
selection.	 One	 for	 unfolded	 proteins	 containing	
no	 specific	 tag	 and	 dependent	 on	 the	 MecA	
adaptor	 for	 efficient	 ClpC1	 oligomerization	 and	
activation,	 and	 a	 second	 MecA-independent	
pathway	 that	 depends	 specifically	 on	 the	
presence	 of	 protein	 sequences	 containing	
phosphorylated	 arginines	 (5,	 25).	 In	 contrast	 to	
BsClpC,	MtbClpC1	 does	 not	 require	 any	 cofactor	
for	 activity.	 In	 the	 presence	 of	 ATP	 it	 can,	 in	
association	with	MtbClpP1P2,	efficiently	degrade	
unfolded	proteins	like	casein	(2).		
Despite	 these	 differences,	 the	 mechanism	 of	
these	 homologous	 enzymes	 seems	 to	 be	
conserved	 between	 species,	 and	 studying	 the	
effects	 of	 cyclomarin	 and	 ArgP	 on	 protein	
degradation	 by	 MtbClpC1P1P2	 could	 give	
important	mechanistic	insights.		
One	 interesting	 question	 that	 arises	 is	 whether	
ArgP	 binding	 is	 able	 to	 block	 casein	 degradation	
as	 it	 does	 in	 BsClpC.	 We	 therefore	 compared	
degradation	 of	 FITC-casein	 in	 the	 presence	 and	
absence	 of	 ArgP.	 ArgP	 caused	 a	 significant	
inhibition	 (up	 to	 55%,	 Fig5d)	 of	 FITC-casein	
degradation,	but	 it	did	not	 completely	block	 this	
process	even	at	very	high	ArgP	concentrations.	By	
contrast,	 in	 the	presence	of	cyclomarin	 (20	µM),	
no	inhibition	of	proteolysis	was	observed	(Fig5d).		
	
ClpC1	forms	high	oligomeric	species	in	solution	
We	 used	 SAXS	 as	 a	 complementary	 method	 to	
obtain	 information	on	 the	effect	of	drug	binding	
on	 ClpC1	 structure.	 Compared	 to	 X-ray	
diffraction,	SAXS	has	a	modest	resolution	but	can	
provide	 information	 on	 several	 global	
parameters:	 the	 radius	 of	 gyration;	 the	 largest	
intraparticle	distance;	the	particle	shape;	and	the	
degree	of	folding,	denaturation,	or	disorder	(26).	
All	 these	 parameters	 can	 be	 good	 reporters	 for	
significant	 structural	 changes	 promoted	 by	 drug	
binding.	 In	 addition,	 SAXS	 does	 not	 require	 the	
preparation	 of	 highly	 concentrated	 deuterated	
samples,	allowing	the	study	of	ClpC1	structure	in	
native	like	solution	conditions.	
Our	 first	 SAXS	measurements	 in	 batch	 format	 in	
the	 presence	 of	 ATP	 revealed	 the	 presence	 of	
very	high	molecular	weight	 species	 incompatible	
with	a	ClpC1	hexamer.	As	MtbClpC1	is	inherently	
prone	 to	 aggregation,	 known	 to	 seriously	 affect	
SAXS	data	interpretation,	we	concluded	that	part	
of	the	MtbClpC1	sample	could	be	aggregated.	To	
overcome	 this	 problem,	 we	 turned	 to	 size-
exclusion	chromatography	coupled	to	SAXS	(SEC-
SAXS).	 In	 this	 system,	 the	 sample	 is	 separated	
according	 to	 size	 and	 shape	 before	 SAXS	
measurement,	 this	 way	 removing	 protein	
aggregates	 from	 the	 protein	 samples.	 	 Indeed,	
consistent	with	the	aggregation	hypothesis,	when	
ClpC1	 was	 loaded	 on	 a	 Superose	 6	 10/300	 GL	
column,	 the	 chromatograms	 of	 ClpC1	 showed	
two	distinct	peaks:	a	small	peak	directly	after	the	
void	 volume	 followed	 by	 a	 second	 broad	 peak	
(Fig	6a).		The	scattering	signal	at	the	second	peak	
was	 relatively	 stable	with	 a	 radius	of	 gyration	 in	
the	 range	 of	 8	 nm	 (Table	 S1),	 but	 reduces	
significantly	 to	 7.6	 nm	 at	 the	 end	 of	 the	 peak,	
indicating	 either	 structural	 flexibility	 or	
overlapping	 oligomeric	 states.	 Surprisingly,	 this	
radius	 of	 gyration	was	 again	 clearly	 inconsistent	
with	 a	 ClpC1	 hexamer	 (radius	 of	 gyration	 5.53	
nm)	 representing	 instead	 bigger	 complexes.	
Apparently,	in	the	conditions	used	(Hepes	50	mM	
pH	7.5,	KCl	100	mM,	glycerol	10%,	MgCl2	4	mM	
and	 ATP	 1	 mM,	 ClpC	 1	 mg/ml),	 the	 hexamer	 is	
not	 the	dominant	 species,	 and	ClpC1	 appears	 to	
exist	in	a	rather	distinct	molecular	organization.		
Recently,	 Carroni	 et	 al,	 using	 cryo-electron	
microscopy	 (cryo-EM)	 and	mutagenesis,	 showed	
that	 S.	 aureus	 ClpC	 (SaClpC)	 can	 exist	 in	 a	
decameric	 resting	 state	 formed	 through	 ClpC	
middle	 domains	 establishing	 intermolecular	
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 8 
head-to-head	 contacts	 (27).	 This	 head	 to	 head	
contacts	 allow	 the	docking	of	 two	 layers	of	ClpC	
molecules	 arranged	 in	 a	 helical	 conformation.	
Despite	 their	 oligomerization,	 these	 structures	
are	 however	 highly	 dynamic	 -	 as	 the	 peripheral	
subunits	are	 likely	 in	exchange	–	 suggesting	 that	
higher	order	species	can	exist	in	equilibrium.		
As	 the	middle	domain	of	MtbClpC1	 is	 conserved	
compared	 to	 SaClpC,	 and	 to	 better	 understand	
how	 our	 SAXS	 data	 could	 relate	 to	 the	 resting	
state	 cryo-EM	 structure,	 we	 averaged	 frames	
from	the	center	of	the	peak	and	the	trailing	end.	
SAXS	 estimates	 the	 molecular	 weight	 at	 the	
center	of	 the	peak	between	1100	and	1400	kDa,	
compatible	with	 12-	 or	 14-mers	 (Table	 S1).	 	 For	
the	 tail,	 the	 estimated	weight	 between	 860	 and	
1200	kDa	 is	 in	better	agreement	with	10-	or	12-
mers.	 Bead	 modeling	 based	 on	 both	 curves	
resulted	 in	 curling	 stone	 shaped	 objects,	 whose	
main	body	matches	the	reported	EM	data	in	size	
and	 shape	 (Fig6b).	An	artifact	 resulting	 from	 the	
presence	 of	 several	 oligomer	 populations	 in	 the	
sample	 is	 observed	 in	 the	 form	 of	 an	 appendix.	
Direct	comparison	of	the	SAXS	curve	from	the	tail	
with	 the	 atomistic	 model	 gives	 a	 surprisingly	
good	fit	(χ2	=3.4,	Fig	6c),	given	that	the	SAXS	curve	
represents	 an	 ensemble	 of	 states.	 Considering	
the	 similarities	 between	 our	 data	 and	 the	
previously	reported	cryo-EM	structure,	 it	 is	 likely	
that	MtbClpC1	 can	 form	 a	 resting	 state	 with	 a	
large	 part	 of	 the	 population	 representing	 even	
higher	 oligomers	 than	 decamers.	 This	 difference	
could	 derive	 from	 a	 concentration	 dependent	
oligomeric	 equilibrium	which	would	 explain	why	
MtbClpC1	seems	larger	in	our	study	as	compared	
to	the	SEC-MALS	data	presented	by	Carroni	et	al	
(27).	 In	 fact,	 crosslinking	 data	 from	 the	 same	
study	 already	 suggested	 the	 presence	 of	
complexes	 bigger	 than	 the	 EM	 decameric	
structure	 (27).	 While	 we	 could	 not	 detect	 the	
hexamer	 in	 solution,	 the	 fact	 that	 in	 the	 same	
conditions	 ClpC1	 is	 active,	 catalyzing	 the	
degradation	of	GFPssra	and	casein	 in	association	
with	 ClpP1P2,	 suggests	 that	 a	 part	 of	 the	
population	exists	as	a	hexamer.		
We	 proceeded	 testing	 if	 the	 natural	 product	
antibiotics	 or	 ArgP	 targeting	 ClpC1	 could	 affect	
the	distribution	of	ClpC1	between	a	resting	state	
and	 an	 active	 hexameric	 form.	 	 The	 addition	 of	
ecumicin	 (20	µM),	 cyclomarin	 (20	µM)	and	ArgP	
(200	 µM)	 to	 the	 SEC	 buffer	 lead	 only	 to	 small	
changes	 in	 the	 averaged	 SAXS	 curve	 (Fig	 S8	 &	
Table	 S1).	 As	 the	 curve	 is	 not	 stable,	 the	
differences	are	too	small	 to	allow	any	statement	
about	 local	 structural	 rearrangement.	 It	 appears	
however	 that	 the	 natural	 antibiotics	 tested	 do	
not	 affect	 the	 ClpC1	 oligomer	 equilibrium	
significantly.		
	
Discussion:		
The	 structural	 characterization	 of	 AAA+	 proteins	
involved	in	molecular	recognition	and	unfolding	is	
usually	 a	 complex	 task.	 Whereas	 their	 intrinsic	
heterogeneity	 normally	 results	 in	 difficult	
crystallization,	 their	 oligomeric	 organization	 and	
large	size	makes	their	study	by	NMR	challenging.	
So	 far,	 no	 X-ray	 structure	 is	 available	 for	
MtbClpC1	 and,	 as	 reported	 here,	 the	 full-length	
protein	 and	 its	 domains	 have	 intrinsic	 low	
solubility.	Adding	further	complexity	to	the	study	
of	 the	system,	we	show	here	 that	MtbClpC1	can	
exist	 in	 an	 equilibrium	 between	 different	
oligomeric	 states.	 The	 existence	 of	 a	 resting	
decameric	 state	 formed	 by	 the	 association	 of	
head-to-head	 contacts	 between	 coiled-coil	
middle	 domains	 of	 ClpC	 was	 recently	 described	
by	 Carroni	 et	 al	 (27).	 The	middle	 domains	 were	
proposed	 to	 repress	 the	 activity	 of	 ClpC	 by	
forming	 a	 highly	 dynamic	 resting	 state	 that	 can	
block	substrate	binding	or	ClpP	interaction.	Quite	
striking	 is	 the	 observation	 that	 a	 single	 point	
mutation	 in	 the	 middle	 domain	 can	 disrupt	 the	
resting	 state	 and	 result	 in	 the	 formation	 of	 an	
active	hexamer	even	in	the	absence	of	the	MecA	
adaptor	(27).	Consistent	with	the	conservation	of	
the	 key	 residues	 between	MtbClpC1	 and	 SaClpC		
(27),	 	 our	 SAXS	 data	 suggests	 that	 a	 similar	
structure	 is	 predominant	 versus	 the	 active	
hexameric	form	in	MtbClpC1.		However,	contrary	
to	the	case	of	S.	aureus	or	B.	subtilis,	where	MecA	
was	 proposed	 to	 modulate	 this	 equilibrium,	 in	
the	 case	 of	 Mtb	 it	 is	 not	 clear	 how	 the	
distribution	between	resting	state	and	hexameric	
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 9 
form	 occurs.	 N-terminal	 domains	 are	 packed	
between	 middle	 domains	 in	 this	 resting	 state,	
and	were	suggested	to	play	a	role	in	the	complex	
stability	by	fluctuating	between	a	hidden	position	
to	 an	 exposed	 one,	 available	 to	 adaptors	 or	
substrates.	One	hypothesis	is	that	the	equilibrium	
could	 be	 modulated	 by	 substrates	 or	 natural	
product	antibiotics.	However,	we	could	show	that	
the	 addition	 of	 cyclomarin,	 ecumicin	 or	 ArgP	
ligand	 appears	 not	 to	 shift	 ClpC1	 distribution.	
With	 the	 current	 data,	 we	 cannot	 exclude	 that	
binding	 of	 a	 bulkier	 substrate	 can	 shift	 the	
equilibrium	 towards	a	 state	where	 the	NTDs	are	
not	constrained	thus	activating	the	unfoldase.		
Whereas	 natural	 product	 antibiotics	 appear	 not	
to	 influence	 ClpC1	 oligomerization	 equilibrium,	
we	were	unable	to	obtain	convincing	evidence	for	
ecumicin	or	PZA	binding	to	the	isolated	MtbClpC1	
NTD.	This	result	 is	 intriguing,	as	mutations	 in	the	
NTD	 domain	 have	 been	 associated	 with	
resistance	to	ecumicin	and	PZA	(10).	With	regard	
to	 ecumicin,	 we	 and	 others	 (10)	 were	 able	 to	
demonstrate	 biochemical	 activity,	 namely	
activating	 ATPase	 activity.	 Most	 likely,	 ecumicin	
requires	 full	 length	 ClpC1	 or	 an	 oligomeric	
structure	 for	 binding	 and	 ATPase	 activation.	
Possibly	 the	 binding	 site	 is	 located	 at	 the	
interface	 of	 the	NTD	 and	D1	 domain,	which	 can	
explain	the	ATPase	activation	by	ecumicin.	In	this	
case,	 disrupting	 part	 of	 the	 binding	 site,	 the	 N-
terminal	interface	in	the	resistant	mutants,	might	
be	 sufficient	 for	 reduced	binding	 affinity	 in	 vivo.	
Small	 CSPs	 were	 evident	 on	 the	 NTD	 NMR	
spectrum	 for	 ecumicin	 in	 the	 regions	 where	
resistant	 mutations	 are	 located,	 suggesting	 that	
this	 region	could	be	part	of	 the	putative	binding	
site	(FigS2).	In	the	case	of	PZA,	an	efficient	“dirty	
drug”	with	multiple	 reported	cellular	 targets,	we	
cannot	 exclude	 that	 resistance	 derives	 from	 the	
modulation	of	protein	homeostasis	for	any	of	the	
other	 targets,	 for	 example	 preventing	 or	
increasing	substrate	degradation	(28).		
Using	 NMR,	 we	 could	 show	 that,	 although	
cyclomarin	 binds	 with	 high	 affinity	 to	 the	 ClpC1	
NTD,	 the	 domain	 dynamics	 are	 not	 modified.	
MtbClpC1	 NTD	 is	 a	 rather	 rigid	 domain,	 and	
showed	no	millisecond	dynamics	in	the	apo	state.	
Also,	 cyclomarin	 binding	 does	 not	 result	 in	 peak	
broadening	or	loss	of	intensity	that	might	indicate	
the	 presence	 of	 an	 alternative	 state.	 These	
observations	 rule	 out	 the	 existence	 of	 hidden	
conformations	 not	 captured	 by	 previous	 X-ray	
studies	(8).		
Finally,	 our	 finding	 that	 ArgP	 binding	 induces	
millisecond	 dynamics	 in	 the	 MtbClpC1	 NTD	
domain	is	a	new	and	important	clue	about	ClpC1	
mechanisms.	 Particularly	 when	 no	 alternative	
conformations	 were	 reported	 in	 the	 X-ray	
structure	 of	 BsClpC	 with	 ArgP-bound,	 and	
because	 no	 structural	 changes	 were	 observed	
with	 arginine	 or	 phosphoserine.	 While	 we	
excluded	 unfolding	 and	 transient-binding	 as	
potential	 explanations	 for	 the	 observed	
dynamics,	 we	 were	 unable	 to	 pursue	 structural	
determination	 since	 approximately	 half	 of	 the	
residues	 in	 the	 ArgP-bound	 NTD	 are	 NMR	
invisible.	 ArgP	 binding	 results	 in	 a	 significant	
increase	 in	 tyrosine	 fluorescence	and	a	dramatic	
change	 in	 the	 stability	of	 this	domain.	While	 the	
increased	 fluorescence	 could	 result	 from	 subtle	
changes	 in	 tyrosine	 side	 chains	 in	 a	 region	
densely	packed	with	aromatic	residues	(three	Phe	
and	 two	 Tyr,	 FigS5)	 the	 increased	 stability	 could	
derive	from	the	ArgP	binding	preferentially	to	the	
folded	state.	The	exact	relationship	between	ArgP	
induced	 dynamics	 and	 the	 functional	 cycle	 of	
MtbClpC1	 is	 currently	 not	 clear.	 Do	 dynamics	
promote	target	binding	through	ArgP	recognition	
by	 allowing	 multiple	 transient	 interaction	 sites	
with	 the	 incoming	 substrate?	 Conformational	
heterogeneity	and	dynamics	 in	substrate	binding	
sites	 have	 been	 proposed	 to	 increase	 substrate	
recognition	 efficiency,	 and	 at	 the	 same	 time	 to	
facilitate	 substrate	 handover	 to	 downstream	
elements,	 by	 making	 a	 multitude	 of	 transient	
weak	 interactions	 with	 the	 substrate	 which	 can	
be	 easily	 broken	 (29).	 In	 fact,	 a	 single	
phosphorylated	 arginine	 in	 a	 protein	 has	 been	
shown	to	be	sufficient	for	efficient	ClpC-mediated	
degradation.	 Thus	 ClpC’s	 molecular	 recognition	
mechanism	must	be	highly	efficient,	 for	example	
1	 mM	 of	 free	 ArgP	 does	 not	 completely	 block	
protein	 binding,	 which	 may	 appear	 inconsistent	
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with	the	micromolar	Kd	that	we	and	others	report	
for	ArgP	binding	to	the	 isolated	NTD	(5).	Despite	
this,	 the	 fact	 that	 cyclomarin	 cannot	 block	
arginine	phosphorylated	protein	binding	appears	
to	 contradict	 the	 hypothesis	 that	 dynamics	 are	
fundamental	 for	 substrate	 association	 to	 the	
NTD,	 not	 excluding	 however,	 that	 they	 are	
relevant	 for	 subsequent	 steps	 –	 for	 example	
substrate	release	to	the	D1	pore	(Fig	7).	Another	
possibility	 is	 that	 the	 observed	 conformational 
dynamics	 could	modulate	 the	 positioning	 of	 the	
NTD	related	to	the	D1	pore.	Indeed,	studies	with	
the	 type	 II	 eukaryotic	 homologue	 p97/Cdc48	
ATPase	 complex	 which	 shares	 the	 NTD-D1-D2	
architecture	 with	 ClpC1,	 have	 stressed	 the	
mechanistic	 relevance	 of	 the	 interface	 between	
NTD/D1	 and	 the	 denominated	 up/down	
equilibrium	 of	 the	 highly	 mobile	 NTDs	 (30).	 In	
p97/Cdc48,	 NTDs	 have	 been	 shown	 to	 adopt,	
depending	 on	 the	 nucleotide	 bound,	 either	 a	
coplanar	 (down)	 or	 elevated	 (up)	 position	 with	
respect	to	the	D1	domain	(30).	Increasing	the	life	
time	of	the	NTDs	“up	state“,	thereby	holding	the	
substrate	 next	 to	 the	 D1	 pore	 would	 promote	
substrate	recognition,	while	supporting	the	down	
state	 would	 prevent	 substrate	 recognition,	
nevertheless	 exposing	 the	 D1	 domain	 pore.	 In	
E.coli	 ClpA,	 a	 close	bacterial	 homologue	of	 ClpC,	
removal	 of	 NTD	 is	 known	 to	 seriously	 impair	
recognition	 of	 substrates	 bearing	 the	 SsrA-
targeting	 sequence,	 but	 to	 have	 only	 a	 modest	
effect	 on	 degradation	 of	 unfolded	 proteins	 (31).		
In	 other	 words,	 NTDs	 may	 work	 as	 recognition	
domains	for	certain	substrates,	while	at	the	same	
time	blocking	the	D1	domain	and	preventing	free	
access	 for	 unfolded	 proteins.	 This	 differential	
effect	on	certain	substrates	was	the	basis	for	the	
suggested	 role	 for	 the	 NTDs	 as	 an	 “entropic	
brush”	 that	 prevents	 nonspecific	 degradation	 of	
proteins	by	blocking	acess	to	the	D1	ring	(32).	 In	
our	view	the	competition	between	recognition	of	
ArgP-labelled	 and	 unfolded	 protein,	 can	
simultaneously	 explain	 the	 inhibition	 of	 casein	
degradation	 by	 ArgP,	 and	 the	 effect	 of	
cyclomarin,	 which	 is	 able	 to	 completely	 abolish	
this	inhibition	of	casein	hydrolysis.		
Put	 together,	 our	work	 shows	 that	 ArgP	 binding	
to	 MtbClpC1NTD	 leads	 to	 widespread	 domain	
millisecond	dynamics	and	that	cyclomarin	 is	able	
to	 block	 this	 process.	While,	 it	 is	 surely	 not	 the	
absence	of	ClpC1	NTD	dynamics	 that	kills	TB	but	
likely	 its	 derived	 functional	 consequences,	 for	
example	 blocking	 the	 ArgP	 pathway,	 this	 work	
sheds	 light	 on	 ClpC	 mechanism.	 Rather	 than	 a	
static	 interaction,	 ArgP	 labelled	 proteins	 binding	
to	ClpC	must	be	understood	as	a	highly	dynamic	
process.	 Cyclomarin	 is	 therefore	 a	 unique	
example	of	a	drug	whose	mode	of	action	relies	on	
the	 restriction	 of	 protein	 dynamics	 induced	 by	
substrate	binding.		
	
	
Experimental	Procedures:		
ArgP	 was	 obtained	 from	 Sigma.	 Cyclomarin	 and	
desoxycyclomarin	were	synthetized	as	previously	
described	 (33).	 MtbClpC1,	 MtbClpP1,	 MtbClpP2	
were	 expressed	 and	 purified	 as	 previously	
described	 (2).	 Bacillus	 stearothermophilus	 mcsB	
was	cloned	 into	a	pet28a+	vector	and	expressed	
and	 purified	 as	 previously	 described	 (5).	
MtbClpC1	 domains:	 NTD	 corresponding	 to	
residues	 1-145,	 D1	 corresponding	 to	 residues	
165-493,	 D2	 corresponding	 to	 residues	 494-849,	
NTD-D1	 corresponding	 to	 1-493	 and	 D1-D2	
corresponding	 to	 165-849	 were	 cloned	 into	 a	
pet28a+	 vector	 by	 Genscript.	 Unless	 otherwise	
noted,	 the	 purification	 protocol	 consisted	 of	 an	
initial	NiNTA	affinity	chromatography	step	taking	
advantage	of	the	histidine	tag,	followed	by	a	size	
exclusion	 step	 using	 a	 Hiload	 16/600	 Superdex	
200	pg	column.	FITC-casein,	GFPssra	degradation	
and	ATP	hydrolysis	were	measured,	as	previously	
described	(2).	For	DLS	measurements,	200	µl	of	a	
1.1	mg/ml	ClpC1	NTD	solutions	with	and	without	
ArgP	(1	mM)	were	used.		
Far	UV	CD	spectra	were	acquired	on	a	Jasco	J-810	
spectropolarimeter	 continuously	 purged	 with	
nitrogen	 and	 thermostated	 at	 20	 °C.	 Briefly,	 a	
solution	of	ClpC1	NTD	(5	µM)	in	Tris	pH	7.5	NaCl	
150	mM	with/without	ArgP	 (1	mM)	was	used	 to	
obtain	CD	spectra	between	205	and	250	nM.		
Intrinsic	tyrosine	fluorescence	was	measured	in	a	
Varian	Cary	Eclipse	spectrofluorimeter	using	a	60	
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µM	solution	of	ClpC1	NTD.	Samples	were	excited	
at	 280	 nm,	 and	 fluorescence	 spectra	 were	
measured	 from	 290	 to	 350	 nm.	 Samples	 in	 the	
presence	of	ANS	(50	µM)	were	excited	at	370	nm,	
and	 fluorescence	 spectra	 were	 measured	 from	
400	to	600	nm.	
	
Degree	of	saturation	of	ClpC1	NTD		
The	degree	of	saturation	of	ClpC1	NTD	with	ArgP	
was	calculated	using	the	equation:		
 
 !"! = 12 1 + " '! ' + ()! '
− 1 + ["]'[!]' + ()[!]' - − 4 ["]'[!]0  
	
where	 [L]0	 is	 initial	 ligand,	 [P]0	 is	 initial	 protein	
and	PL	is	protein	ligand	complex.		
	
SAXS	data	collection	and	analysis	
	
SEC-SAXS	data	were	collected	at	ESRF	BM29	(34,	
35).	 	 The	 HPLC	 system	 (Shimadzu,	 Farance)	 was	
directly	 coupled	 to	 the	 1.8	 mm	 flow-through	
capillary	of	SAXS	exposure	unit.	The	flow	rate	for	
all	online	experiments	was	0.3	mL/min.	SAXS	data	
collection	 was	 performed	 continuously	
throughout	 the	 chromatography	 run	 at	 a	 frame	
rate	of	1	Hz	with	a	Pilatus	1M	detector	 (Dectris)	
at	the	distance	of	2.876	m	from	the	capillary.	The	
scattering	of	pure	water	was	used	to	calibrate	the	
intensity	to	absolute	units	(36).	The	X-ray	energy	
was	12.5	keV	and	the	accessible	q-range	0.07	nm-
1	 to	 4.9	 nm-1.	 The	 incoming	 flux	 at	 the	 sample	
position	was	in	the	order	of	1012	photons/s	in	700	
×	 700	 µm2.	 A	 summary	 of	 the	 acquisition	
parameters	 is	 given	 in	 table	 S1.	All	 images	were	
automatically	 azimuthally	 averaged	 with	 pyFAI	
(37)	 and	 corrected	 for	 background	 scattering	 by	
the	 online	 processing	 pipeline	 (38).	 For	 each	
frame,	the	forward	scattering	intensity	and	radius	
of	 gyration	 were	 determined	 according	 to	 the	
Guinier	 approximation	
(https://github.com/kif/freesas).	 	 For	 each	 run,	
regions	 of	 20	 to	 80	 frames	 were	 averaged	 for	
further	 characterization.	 Data	 at	 small	 angles	
before	 the	 Guinier-region	 was	 removed	 before	
further	 data	 analysis	 to	 avoid	 experimental	
artefacts.	
Pair	 distribution	 functions	were	 calculated	 using	
GNOM	 (39).	 20	 ab-initio	 models	 each	 were	
calculated	 in	 C1	 symmetry,	 using	 DAMMIF	 (40)	
and	 averaged,	 aligned	 and	 compared	 using	
DAMAVER	 (41).	 The	 scattering	 curve	of	 the	ClpC	
decamer	 (27)	 was	 predicted	 and	 fitted	 to	
experimental	data	using	Crysol	3	(42).	
	
NMR	experiments		
All	NMR	experiments	were	performed	on	Bruker	
Avance	 III	 spectrometers,	 equipped	 with	
cryogenically	cooled	TCI	probeheads,	operating	at	
magnetic	 field	 strengths	 corresponding	 to	 1H	
Larmor	 frequencies	 of	 850,	 700	 and	 600	
respectively.	The	sample	temperature	was	set	to	
37	°C,	unless	stated	otherwise.		
Sequence-specific	 resonance	 assignments	 of	
ClpC1	NTD	
	
Apo	ClpC1	NTD	was	assigned	in	NMR	buffer	pH	6	
(50mM	MES,	100mM	NaCl,	5%	D2O)	and	 in	NMR	
buffer	 pH	7.5	 (50mM	Tris,	 50mM	NaCl,	 5%	D2O)	
at	 a	 protein	 concentration	 of	 0.8mM	 at	 a	 1H	
Larmor	 frequency	 of	 600.	 The	 following	
experiments	 were	 performed:	 2D	 15N-1H	 BEST	
HSQC,	 3D	 BEST	 HNCO,	 3D	 BEST-TROSY	 HNcaCO,	
3D	 BEST	 HNCA,	 3D	 BEST	 HNcoCA,	 3D	 BEST	
HNcoCACB	and	3D	BEST	HNCACB	(43).		
The	same	experimental	conditions	were	used	for	
the	assignment	of	ClpC1	NTD	 in	 the	presence	of	
cyclomarin,	 except	 for	 a	 lower	 protein	
concentration	due	to	low	solubility	of	cyclomarin	
(0.2	mM	ClpC1	NTD,	0.22	mM	cyclomarin).	DMSO	
controls	were	also	measured.	
For	the	assignment	of	ClpC1	NTD	in	the	presence	
of	 ArgP	 and	 ArgP	 plus	 cyclomarin,	 15N-1H	 BEST	
HSQC,	BEST	HNCO	and	BEST	HNCA	spectra	were	
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recorded	 at	 a	 1H	 Larmor	 frequency	 of	 850	MHz.	
Assignment	 was	 performed	 by	 following	 the	
chemical	 shifts	 of	 backbone	 amide,	 Ca	 and	 CO	
peaks	 in	 apo	 and	 ligand	 bound	 spectra.	 The	
sample	conditions	used	were:	0.2	mM	ClpC1	NTD	
and	2	mM	ArgP	or	0.2	mM	ClpC1	NTD,	2	mM	ArgP	
and	0.22	mM	cyclomarin	in	NMR	buffer	pH	6.	
Data	 processing	 and	 analysis	 were	 performed	
using	 the	 NMRPipe	 software	 package	 (44)	 and	
CCPN	software	(45).	
	
Titration	of	cyclomarin	into	MtbClpC1	NTD:	
	
For	 the	 cyclomarin	 titration	 four	 titration	 points	
were	 measured	 with	 0.2	 mM	 MtbClpC1	 NTD	
each.	 The	 DMSO	 content	 in	 all	 samples	was	 2.2	
%.	 The	 measured	 ratios	 between	 the	 NTD	 and	
cyclomarin	 were	 1:0,	 1:1.1,	 1:1.5	 and	 1:2.	 No	
chemical	 shift	 changes	 were	 observed	 after	 a	
ratio	 of	 1:1.1	 MtbClpC1	 NTD:cyclomarin.	 Ratio	
used	for	experiments	1:1.1.	
	
Titration	of	ArgP	into	MtbClpC1	NTD:	
	
Five	titration	points	were	measured	with	0.3	mM	
MtbClpC1	 NTD	 each.	 The	 DMSO	 content	 in	 all	
samples	was	0.6	%.	The	measured	ratios	between	
the	 NTD	 and	 ArgP	 were	 1:0,	 1:0.5,	 1:1,	 1:2	 and	
1:10.	No	intensity	changes	were	observed	after	a	
ratio	 1:2	MtbClpC1	 NTD	 :	 ArgP.	 Ratio	 used	 for	
experiments	1:10.	
	
Titration	 of	 cyclomarin	 and	 ArgP	 into	MtbClpC1	
NTD:	
	
Four	 different	 samples	 were	 measured	 for	 the	
titration	 of	MtbClpC1	 NTD	 with	 cyclomarin	 and	
ArgP.	All	samples	contained	4.2	%	DMSO	and	0.2	
mM	MtbClpC1	NTD.	We	measured	one	reference	
sample,	 one	 sample	 with	 0.22	 mM	 cyclomarin	
added,	one	sample	with	0.22	mM	cyclomarin	and	
0.2	 mM	 ArgP	 and	 one	 sample	 containing	 0.22	
mM	cyclomarin	and	2	mM	ArgP.	
	
Titration	of	Ecumicin	into	MtbClpC1	NTD:	
	
Three	titration	points	were	measured	with	0.2	
mM	MtbClpC1	NTD	each.	The	DMSO	content	in	
all	samples	was	4	%.	The	measured	ratios	
between	the	NTD	and	Ecumicin	were	1:0,	1:1,	
and	1:2.	Due	to	the	insolubility	of	Ecumicin	no	
higher	concentrations	of	Ecumicin	could	be	
measured.	
	
Titration	of	Pyrazinamide	into	MtbClpC1	NTD:	
	
Three	 titration	 points	 were	 measured	 with	 0.2	
mM	MtbClpC1	 NTD	 each.	 The	 DMSO	 content	 in	
all	 samples	 was	 2	 %.	 The	 measured	 ratios	
between	 the	 NTD	 and	 ArgP	 were	 1:0,	 1:1	 and	
1:10.	No	intensity	or	chemical	shift	changes	were	
observed	 at	 any	 measured	 Pyrazinamide	
concentration.	
BEST-TROSY	 type	 (43)	 15N	 CPMG	 relaxation	
dispersion	experiments	were	performed	with	the	
pulse	 scheme	 described	 by	 Franco	 et	 al	 (46)	 at	
static	 magnetic	 field	 strengths	 of	 700	 and	 850	
MHz,	at	a	sample	temperature	of	37	°C.	Effective	
relaxation	rate	constants,	R2eff,	were	measured	at	
11	 (700	MHz)	and	13	 (850	MHz)	different	CPMG	
frequencies	 and	 derived	 from	 the	 commonly	
employed	 two-point	measurement	 scheme	 (47),	
R2eff=-1/T·ln(I/I0),	where	I	is	the	peak	intensities	in	
the	experiment	with	the	CPMG	pulse	train	and	I0	
the	 one	 in	 a	 reference	 experiment	 without	
relaxation	 delay.	 T	 is	 the	 total	 relaxation	 delay,	
which	 was	 chosen	 as	 60	 ms	 and	 40	 ms	 in	 the	
experiments	 performed	 at	 700	 and	 850	 MHz,	
respectively.	 Peak	 heights	 and	 error	 margins	
were	 extracted	 in	 the	 software	 nmrView	
(OneMoon	 Scientific).	 A	 two-state	 exchange	
model	was	fitted	jointly	to	the	dispersion	data	of	
24	 residues	 using	 the	 program	 ChemEx	 (48).	
Briefly,	 the	 program	 involves	 the	 integration	 of	
the	 Bloch-McConnell	 equations	 throughout	 the	
explicit	train	of	CPMG	pulses,	taking	into	account	
offset	 effects	 and	 finite	 pulse	 lengths.	 Error	
estimates	 were	 obtained	 from	 Monte	 Carlo	
simulations.	 The	 fit	 curves	 from	 the	 joint	 fit	 are	
shown	 in	 Fig	 S7,	 and	 a	 table	 of	 residue-wise	
chemical-shift	differences	is	provided	in	Fig	S5c.	
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Figure	Legends:	
Figure	1.	Structural	model	of	MtbClpC1	showing	drug-resistant	mutations	in	the	N-terminal	domain.	
(a)	Side	and	top	view	of	MtbClpC1	structural	model	based	on	BsClpC	in	complex	with	MecA	(pdb	3j3s).	In	
gray	NTD	and	linker	region,	in	blue	D1	domain	and	in	green	D2	domain.	NTD	and	linker	are	predicted	to	
be	 mobile.	 (b)	MtbClpC1	 NTD	 (pdb	 3wdb)	 is	 the	 assumed	 target	 of	 the	 natural	 product	 antibiotics	
ecumicin,	 cyclomarin	 and	 lassomycin.	 Mutations	 in	 pyrazinamide-resistant	 strains	 have	 also	 been	
mapped	 to	 this	domain.	Depicted	as	pink	 spheres	are	ecumicin-resistant	mutations	 (L92S,	 L96P,	 L92F)	
(10),	in	yellow,	lassomycin-resistant	(Q17R,	Q17H,	R21S,	P79T)	(11)	and	in	green	pyrazinamide-resistant	
(G99D	 (7)	 and	 L88V,	 G99D,	 I108T,	 R114L	 mutations	 (6)).	 The	 crystal	 structure	 of	 cyclomarin-bound	
MtbClpC1	 NTD	 is	 shown	 in	 Figure	 2d.c)	 Binding	 site	 of	 cyclomarin	 (yellow)	 and	 ArgP	 (red)	 on	 the	
MtbClpC1	NTD.	
 
Figure	2.	NMR	assignment	and	cyclomarin-binding	site	of	MtbClpC1	NTD.	
(a)	 1H-15N	correlated	backbone	amide	spectrum	of	apo	 (black)	and	cyclomarin	bound	 (blue)	MtbClpC1	
NTD.	 95%	 of	 amide	resonances	 of	 the	 apo	 and	 79%	 of	 the	 cyclomarin	 bound	 protein	 spectrum	 have	
been	assigned.	(b)	TALOS+	predicted	helix	propensity	derived	from	NMR	assignments	of	apo	MtbClpC1	
NTD.	In	dark	blue	predicted	helix,	in	white	predicted	loop	and	as	a	gray	background	helical	parts	in	the	
X-ray	 structure	of	MtbClpC1	NTD	 (PDB:	3wdb).	The	 secondary	 structure	 in	 solution	and	 in	 the	crystal,	
seem	 to	 be	 identical.	 (c)	 Combined	 chemical	 shift	 difference	 between	 apo	 and	 cyclomarin-bound	
MtbClpC1	NTD	1H-15N	HSQC	spectra.	Chemical	 shift	differences	are	mapped	on	the	structure	 in	Figure	
2d.	(d)	Chemical	shift	differences	from	Figure	2c	plotted	on	the	structure	of	cyclomarin	bound	MtbClpC1	
NTD	 (PDB:	 3wdc).	 Assigned	backbone	 amides	 are	 shown	 as	 spheres,	 and	unassigned	 residues	 as	 gray	
cartoon.	Chemical	shift	differences	are	plotted	in	a	spectrum	from	blue	to	white,	whereby	blue	indicates	
a	strong	effect.	Cyclomarin	is	shown	as	yellow	sticks	
	
Figure	3.	The	effect	of	ArgP	binding	on	MtbClpC1	NTD.	
(a)	 Sequence	 alignment	of	MtbClpC1	NTD	and	BsClpC	NTD.	 Identical	 residues	 are	highlighted	 in	 black	
and	similar	residues	in	grey.	The	binding	site	of	ArgP	in	BsClpC	NTD	is	circled	in	red.	(b)	Representative	
Isothermal	Calorimetry	Titration	of	ArgP	binding	to	MtbClpC1	NTD	(N	=1.99	±	0.02;	Kd	5.2	±	0.5	µM;	DH	-
4066	±	59	cal/mol;	DS	10.3	cal/mol/deg).	(c)	NTD	is	able	to	pull	down	lysozyme	phosphorylated	by	McsB	
kinase	but	 not	 non-treated	 lysozyme	 (lane	1	 and	4).	 Cyclomarin	 (50	µM)	 is	 unable	 to	block	 substrate	
binding	but	a	reduction	is	observed	with	ArgP	(1	mM).	(d)	1H-15N	correlated	backbone	amide	spectrum	
of	apo	(black),	ArgP	(green),	cyclomarin	(blue)	and	ArgP/cyclomarin	(red)	bound	MtbClpC1	NTD.	95%	of	
apo,	55%	ArgP,	85%	of	cyclomarin	and	75%	of	CymA/ArgP	bound	MtbClpC1	NTD	amide	resonances	are	
NMR	 visible.	 (e)	 Loss	 in	 peak	 intensity	 of	 resonances	 in	 1H-15N	 HSQC	 spectra	 upon	 ArgP	 binding	with	
(red)	or	without	(green)	cyclomarin	added.	(f)	Peak	height	ratio	of	ArgP	bound	MtbClpC1	NTD	(Figure	3d,	
left)	plotted	on	its	structure	(PDB:	3wdb).	Assigned	residues	are	shown	as	spheres,	unassigned	residues	
as	gray	cartoon,	residues	that	disappear	upon	ArgP	binding	as	white	cartoon.	Peak	height	ratio	is	drawn	
as	a	spectrum	from	green	to	white.	Whereby	white	indicates	loss	in	intensity.	Two	arginine-phosphate	
molecules	 (red	 sticks)	 are	 placed	 at	 the	 putative	ArgP	 binding	 site,	 identical	 to	 the	 X-ray	 structure	 of	
BsClpC	NTD	(PDB:	5hbn).		
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Figure	4.	ArgP	induces	millisecond	dynamics	in	MtbClpC1	NTD.	
(a)	Residues	that	exhibit	millisecond	dynamics	plotted	on	the	MtbClpC1	NTD	structure	(PDB:	3wdb).	All	
assigned	residues	are	shown	as	spheres.	Residues	that	have	a	ΔR2,eff	of	5	are	in	yellow,	of	15	orange	and	
of	30	or	more	red.	(b)	Examples	of	CPMG	curves	for	residues	with	a	ΔR2,eff	of	5,	15	or	30.	Apo	MtbClpC1	
NTD	has	no	millisecond	dynamics	(lower	row),	63%	of	all	NMR	visible	residues	experience	ms	dynamics	
when	 ArgP	 is	 bound	 (upper	 row),	 if	 cyclomarin	 is	 added	 before	 ArgP	 no	 more	 ms	 dynamics	 can	 be	
observed,	resulting	in	flat	dispersion	curves	(middle	row).	
	
Figure	5.	Effect	of	ArgP	on	MtbClpC1	NTD	secondary	structure	and	MtbClpC1	substrate	degradation.	
(a)	CD	spectrum	of	apo	(black)	and	ArgP	bound	(green)	MtbClpC1	NTD.	ArgP	binding	does	not	influence	
the	 secondary	 structure	of	MtbClpC1	NTD.	 (b)	ArgP	bound	 (green)	 is	more	 stable	 than	Apo	MtbClpC1	
NTD.	 Intrinsic	tyrosine	fluorescence	was	measured	as	a	function	of	temperature.	(c)	ArgP	(green)	does	
not	change	exposure	of	hydrophobic	regions	in	MtbClpC1	NTD	(black).	Shown	in	gray	the	fluorescence	
of	ANS	 in	buffer.	 (d)	ArgP	 inhibits	FITC-casein	degradation	by	MtbClpC1P1P2	(black	curve).	Cyclomarin	
(20μM)	is	able	to	block	this	inhibition	(blue	curve).		
	
Figure	6.	ClpC1	forms	high	oligomeric	species	in	solution.	
(a)	SEC-SAX	chromatogram	of	MtbClpC1,	showing	the	radius	of	gyration	of	the	eluted	species	(pink)	with	
the	respective	absorbance	at	280	nm	(black).	The	first	peak	immediately	after	the	column	void	volume	
corresponds	to	protein	aggregates.	(b)	DAMMIF	models	obtained	from	MtbClpC1	scattering	curve	in	the	
presence	of	different	ligands	ecumicin	(pink),	cyclomarin	(blue)	and	ArgP	(green).	With	the	exception	of	
the	 appendix,	 an	 artifact	 derived	 from	 sample	 heterogeneity,	 the	 obtained	 model	 fits	 well	 to	 the	
structure	 obtained	 previously	 by	 Cryo-EM	 (pdb	 6em9).	 (c)	 The	 scattering	 curve	 of	 the	 resting	 state	
SaClpC	decamer	was	predicted	and	fitted	using	Crysol	3	 	to	the	experimental	curve	obtained	from	the	
apoMtbClpC1	tail	of	the	peak	.	
	
Figure	7.	MtbClpC1	exists	in	equilibrium	between	a	resting	state	and	a	functional	hexamer.		
MtbClpC1	 can	 form	a	 resting	 state	 in	 equilibrium	with	 the	 active	hexameric	 form.	Phosphorylation	of	
arginines	marks	proteins	for	degradation	by	the	ClpCP	machinery.	Phosphorylated	arginines	bind	to	the	
NTD	where	they	induce	millisecond	dynamics	that	could	either	facilitate	contact	between	different	NTDs	
or	the	transfer	of	the	substrate	to	the	D1	domain	pore.	Although,	cyclomarin	binding	does	not	change	
the	structure	of	the	NTD	or	substrate	binding	it	restricts	ArgP	induced	dynamics.				
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